Primary Care/Hospitalist
RSSArticles
-
Research eyes noninvasive test for endometriosis
Endometriosis is a common health problem for women. An estimated 11% of U.S. women have the gynecologic disorder, which happens when the lining of the uterus grows outside of the uterus.1 In women with endometriosis, when the endometrial tissue enters the abdominal cavity, it attaches to organs in the abdominal and pelvic cavities, such as the ovaries, the intestines, or other organs or tissues. This tissue continues to follow the monthly menstrual cycle, and the resulting bleeding can cause inflammation, scarring, and pain. It is prevalent in 38% of infertile women and in 71-87% of women with chronic pelvic pain.2
-
Boost HPV vaccine uptake in university settings
While public health officials advocate for vaccination against human papillomavirus (HPV) in girls and boys ages 11-12, they also call for vaccination of young women ages 13-26 and males ages 13-21 who have not been previously vaccinated or did not complete the three-dose series.
-
It’s time for a tiered approach to counseling on emergency contraception
A recently published commentary calls for changes in patient counseling for emergency contraception (EC).1 Why? Typical counseling does not take into account the relative effectiveness of available methods or patient characteristics, it asserts.
-
Family Planning Providers Urged to Focus on Campus Sexual Violence Prevention
One in five women is sexually assaulted while in college. A White House Task Force wants to strengthen federal enforcement efforts.
-
Statistics show more use of LARC — How can you maintain momentum?
The latest national statistics show that long-acting reversible contraceptives (LARCs) now follow the Pill, sterilization, and condoms as the most common methods currently used by women in the United States.1 However, with 51% of pregnancies unintended in the United States,2 advocates are pushing to improve access to such effective birth control.
-
Internal Medicine [ALERT]
The United States Preventive Services Task Force (USPSTF) gave a level B recommendation in support of annual low-dose computed tomography (LDCT) to screen for lung cancer in appropriate risk groups. The USPSTF decision was largely based on the National Lung Screening Trial (NLST), a mega-trial (n = 53,454) in the United States that randomized subjects to annual LDCT or chest X-ray. The primary endpoint of the study was lung cancer mortality, and all-cause mortality was a secondary endpoint. Inclusion criteria included at least a 30-pack/year history of smoking (if stopped within 15 years), ability and willingness to complete follow-up for abnormal findings, and absence of problematic comorbidities that might otherwise compromise long-term survival.
-
Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil® 9)
The FDA has approved a 9-valent human papillomavirus (HPV) vaccine. The new vaccine covers five more types of HPV than the previous vaccine and protects against 90% of the HPV strains that cause cervical cancer.1 The new vaccine is marketed by Merck as Gardasil®9.
-
Liraglutide Preserves Beta Cell Function — Well, Kind of…
SYNOPSIS: Fifty-one patients with type 2 diabetes of 2.6 +/- 1.9 years duration and an A1C of 6.8 % completed 4 weeks of intensive insulin therapy in order to eliminate glucose toxicity which is injurious to pancreatic beta cells. Thereafter, patients were randomized to receive daily subcutaneous liraglutide or an equivalent volume of placebo. Serial assessments of beta-cell function following oral glucose tolerance testing was performed at 12 week intervals for 48 weeks. Patients using liraglutide noted a rebust enhancement of beta cell function which was sustained over the course of the trial, yet lost within two weeks after stopping treatment.
-
Clinical Briefs
The Heavy Emotional Costs of Rosacea, Treatment Choices Among the PDE5 Inhibitors, and Screening Asymptomatic Diabetics with CT angiography
-
Ombitasvir, Paritaprevir, and Ritonavir, Dasabuvir Tablets (Viekira™ Pak)
The FDA has approved the fourth new product for the treatment of chronic hepatitis C (HCV) infection since November 2013. The latest is a four fixed-drug combination (3-DAA) that includes paritaprevir, a nonstructure 3/4A protease inhibitor, ombitasvir, an inhibitor of the NS5A replication complex, and copackaged with dasabuvir, a nonnucleoside NS5B polymerase inhibitor. The plasma levels of paritaprevir is boosted with ritonavir, a CYP3A inhibitor to permit once-daily dosing. The combination is marketed by AbbVie, Inc. as Viekira Pak.